Multidrug-resistant tuberculosis

Wulandari, Dika Apriliana; Hartati, Yeni Wahyuni; Ibrahim, Abdullahi Umar; Pitaloka, Dian Ayu Eka; Irkham,

doi:10.1016/j.cca.2024.119701

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Preprint1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Drug Selection Based on Pan-Genomics Genetic Features of Mycobacterium Tuberculosis

sun,

Xu,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

Drug Selection Based on Pan-Genomics Genetic Features of Mycobacterium Tuberculosis

sun,

Xu,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

The Nitrofuran-Warhead-Equipped Spirocyclic Azetidines Show Excellent Activity against Mycobacterium tuberculosis

Komarova,

Vinogradova,

Lukin

et al. 2024

Molecules

View full text Add to dashboard Cite

A series of 21 new 7′H-spiro[azetidine-3,5′-furo [3,4-d]pyrimidine]s substituted at the pyrimidine ring second position were synthesized. The compounds showed high antibacterial in vitro activity against M. tuberculosis. Two compounds had lower minimum inhibitory concentrations against Mtb (H37Rv strain) compared with isoniazid. The novel spirocyclic scaffold shows excellent properties for anti-tuberculosis drug development.

show abstract

The Association between Dyslipidemia and Pulmonary Diseases

Isago

2024

JAT

View full text Add to dashboard Cite

Dyslipidemia is one of the most common diseases worldwide. As a component of metabolic syndrome, the prevalence and mechanism by which dyslipidemia promotes cardiovascular diseases has been well studied, although the relationship between pulmonary diseases is not well understood. Because the lung is a respiratory organ with a large surface area and is exposed to the environment outside the body, it continuously inhales various substances. As a result, pulmonary diseases have a vast diversity, including chronic inflammatory diseases, allergic diseases, cancers, and infectious diseases. Recently, growing evidence has suggested that dyslipidemia plays a role in the pathogenesis and prognosis of various pulmonary diseases. We herein review the current understanding of the relationship between dyslipidemia and pulmonary diseases, including chronic obstructive pulmonary diseases, asthma, and lung cancer, and infectious pulmonary diseases, including community-acquired pneumonia, tuberculosis, nontuberculous mycobacterial pulmonary disease, and COVID-19. In addition, we focus on recent evidence of the utility of statins, specifically 3-hydroxy-3-methylglutaryl-coA reductase inhibitors, in the prevention and treatment of the various pulmonary diseases described above.

show abstract

Multidrug-resistant tuberculosis

Cited by 3 publications

References 110 publications

Drug Selection Based on Pan-Genomics Genetic Features of Mycobacterium Tuberculosis

Drug Selection Based on Pan-Genomics Genetic Features of Mycobacterium Tuberculosis

The Nitrofuran-Warhead-Equipped Spirocyclic Azetidines Show Excellent Activity against Mycobacterium tuberculosis

The Association between Dyslipidemia and Pulmonary Diseases

Contact Info

Product

Resources

About